GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Net Margin %

ALPMY (Astellas Pharma) Net Margin % : -18.87% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Astellas Pharma's Net Income for the three months ended in Dec. 2024 was $-635 Mil. Astellas Pharma's Revenue for the three months ended in Dec. 2024 was $3,364 Mil. Therefore, Astellas Pharma's net margin for the quarter that ended in Dec. 2024 was -18.87%.

The historical rank and industry rank for Astellas Pharma's Net Margin % or its related term are showing as below:

ALPMY' s Net Margin % Range Over the Past 10 Years
Min: -3.08   Med: 11.78   Max: 17.01
Current: -3.08


ALPMY's Net Margin % is ranked worse than
67.89% of 981 companies
in the Drug Manufacturers industry
Industry Median: 4.56 vs ALPMY: -3.08

Astellas Pharma Net Margin % Historical Data

The historical data trend for Astellas Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Net Margin % Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.02 9.65 9.57 6.50 1.06

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.44 -8.03 7.95 7.76 -18.87

Competitive Comparison of Astellas Pharma's Net Margin %

For the Drug Manufacturers - General subindustry, Astellas Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Net Margin % falls into.


;
;

Astellas Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Astellas Pharma's Net Margin for the fiscal year that ended in Mar. 2024 is calculated as

Net Margin=Net Income (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=113.771/10704.091
=1.06 %

Astellas Pharma's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-634.921/3363.848
=-18.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (OTCPK:ALPMY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Astellas Pharma Net Margin % Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.